Vanda Pharmaceuticals Inc. (VNDA) — 10-Q Filings

10-Q Filings (7)

• 10-Q Filing — May 7, 2026
• Vanda's Q3 Sales Up, But Soaring Costs Drive 324% Net Loss Increase — Oct 30, 2025 Risk: high
  Vanda Pharmaceuticals Inc. reported a significant increase in net product sales for the three months ended September 30, 2025, reaching $56.258 million, up from
• Vanda Pharma Q2 Loss Widens on Fanapt Sales Dip — Jul 31, 2025 Risk: high
  Vanda Pharmaceuticals Inc. reported a net loss of $10.5 million for the second quarter of 2025, a significant increase from the net loss of $5.2 million in the
• Vanda Pharmaceuticals Files Q1 2025 10-Q — May 8, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed its quarterly report for the period ending March 31, 2025. The filing details financial positions and activities, including cha
• Vanda Pharmaceuticals Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the thi
• Vanda Pharmaceuticals Files Q2 2024 10-Q — Aug 1, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the first six months of 2024, detailing financial performance a
• Vanda Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. (VNDA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Vanda Pharmaceuticals Inc. reported financial results for the qua

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX